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Abstract: The development of imatinib for the treatment of chronic myeloid leukemia (CML) 
has proven to be an example of medical success in the era of targeted therapy. However, imatinib 
resistance or intolerance occurs in a substantial number of patients. Additionally, patients who 
have progressed beyond the chronic phase of CML do relatively poorly with imatinib therapy. 
Mechanisms of imatinib resistance include BCR-ABL point mutations resulting in decreased 
imatinib binding, as well as mutation-independent causes of resistance such as SRC family kinase 
dysregulation, BCR-ABL gene ampliﬁ  cation, drug inﬂ  ux/efﬂ  ux mechanisms and other poorly 
understood processes. The options for therapy in these patients include stem cell transplantation, 
imatinib dose escalation as well as the use of second-generation tyrosine kinase inhibitors. 
Dasatinib is a second-generation multi-kinase inhibitor with several theoretical and mechanistic 
advantages over imatinib. Moreover, several studies have evaluated dasatinib in patients who 
have progressed on imatinib therapy with encouraging results. Other novel agents such as 
mTOR inhibitors, bosutinib and INNO 406 have also shown promise in this setting. Although 
treatment options have increased, the choice of second-line therapy in patients with CML is 
inﬂ  uenced by concerns surrounding the duration of response as well as toxicity. Consequently, 
there is no agreed upon optimal second-line agent. This paper reviews the current data and 
attempts to address these issues.
Keywords: chronic myeloid leukemia (CML), dasatinib, imatinib, resistance (imatinib resistance), 
nilotinib, tyrosine kinase inhibitor
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disorder with an incidence 
of ∼1 to 2 cases per 100,000 adults which is characterized by the presence of a balanced 
translocation between chromosomes 9 and 22 termed the Philadelphia chromosome.1,2 
The molecular consequence of this translocation is the creation of a novel fusion 
gene (BCR/ABL) and its transcript protein. This protein is a constitutively active 
tyrosine kinase resulting in abnormal clonal expansion of the myeloid hematopoietic 
lineage. CML has a triphasic course with 90% of patients presenting in the chronic 
phase of disease.3 In time, without treatment there will be evidence of progression 
into the accelerated phase and ultimately into blast crisis which is typiﬁ  ed by a lack 
of myeloid differentiation.
A phase 3 randomized study has demonstrated that the tyrosine kinase inhibitor, 
imatinib mesylate, produces major improvements in cytogenetic and hematologic 
response rates, as well as improvements in progression-free survival compared with 
interferon alfa and cytarabine.4 Imatinib inhibits BCR-ABL as well as C-kit and PDGFR 
kinases. However, only a fraction of imatinib-treated patients were able to achieve 
disease eradication at the molecular level (4%) and therapy must be continued indeﬁ  -
nitely.5,6 Moreover, 31% of patients in the imatinib arm were unable to continue therapy 
due to intolerance or progressive disease.4 The event-free survival at 60 months of Biologics: Targets & Therapy 2009:3 206
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follow-up was 83% and 6% of these patients had progressed 
to the accelerated phase or blast crisis.4
Additionally, patients who had progressed beyond the 
chronic phase of CML do relatively poorly. After 4 years 
of imatinib therapy 75% of patients treated with imatinib 
in accelerated phase and 95% of patients diagnosed in blast 
crisis had developed resistance.5 Mechanisms of imatinib 
resistance include BCR-ABL point mutations resulting in 
decreased imatinib binding, as well as mutation independent 
causes of resistance such as Src family kinase dysregulation, 
BCR-ABL gene ampliﬁ  cation, drug inﬂ  ux/efﬂ  ux mecha-
nisms and other poorly understood processes.1,5,7
The role of imatinib has also been evaluated in patients 
with Philadelphia chromosome positive acute lymphoblastic 
leukemia (ALL). Encouraging results were noted in patients 
with Philadelphia positive ALL (Ph+ ALL) utilizing com-
bination chemotherapy in addition to imatinib with DFS at 
2 years of 85%.8 However, the limitations of imatinib in 
this setting were similar to those seen in CML with treat-
ment failures and resistance to therapy viewed as signiﬁ  cant 
problems.
The management of patients who are initially unrespon-
sive to imatinib therapy or who develop resistance includes 
dose escalation of imatinib, switching to alternative tyrosine 
kinase inhibitors such as dasatinib and nilotinib, as well as 
hematopoietic stem cell transplantation for those who are 
candidates. Direct comparisons among these modalities have 
not been performed in a randomized fashion although there 
is considerable evidence demonstrating that second-genera-
tion tyrosine kinase inhibitors are effective in this setting. 
This article will focus on the efﬁ  cacy of dasatinib in patients 
who are intolerant of treatment with imatinib or who have 
developed resistance to imatinib therapy.
Dasatinib structure and function
Dasatinib (formerly BMS-354825) is a potent inhibitor of 
BCR-ABL but differs from imatinib in a number of ways. 
Firstly, dasatinib is a 325-fold more potent inhibitor of 
BCR-ABL in vitro compared with imatinib and, unlike 
imatinib, can bind both the inactive and active conforma-
tions of the kinase molecule. As a result of dasatinib’s less 
stringent binding requirements, it has activity against many 
imatinib-resistant kinase mutations.1 In vitro cell line models 
revealed that dasatinib was active against 21 of 22 imatinib-
resistant BCR-ABL mutations, the lone exception being the 
T315I mutation found within the ATP binding pocket of the 
ABL tyrosine kinase. The frequency of BCR-ABL muta-
tions in patients who are resistant to imatinib ranges from 
40% to 90%, with mutations more commonly found in the 
advanced stages of CML and in Ph+ ALL. Moreover there 
are more than 100 different ABL kinase point mutations 
reported in patients who become imatinib resistant. These 
mutations confer varying degrees of insensitivity to imatinib 
and other tyrosine kinase inhibitors.6
With the exception of the T315I “gatekeeper” mutation, 
dasatinib has shown clinical efﬁ  cacy in patients with many of 
these mutations in the phase I and II studies described below. 
Patients whose CML is resistant to imatinib therapy should 
undergo a mutational analysis to determine if they have this, 
or other potentially clinically signiﬁ  cant mutations. At this 
time there are no guidelines for selecting therapy based on 
mutational ﬁ  ndings alone, although the presence of the T315I 
mutation is predictive of poor response to second-generation 
tyrosine kinase inhibitor (TKI) therapy.
Like imatinib, dasatinib is a multi-kinase inhibitor and 
inhibits other kinases such as Src family kinases (SFK) and 
platelet derived growth factor beta (PDGFR-B). In vitro stud-
ies evaluating the role of Src kinases in imatinib resistance 
have suggested a role for Src activation in non-mutated 
imatinib-resistant cell lines.9 Moreover dasatinib (unlike 
imatinib) is not a substrate for the P-glycoprotein efﬂ  ux 
pump and thus may be able to achieve higher intracellular 
concentrations.7
Additionally, in contrast to imatinib, dasatinib can 
cross the blood brain barrier and may have clinical activity 
in those patients with central nervous system involvement 
by CML. Case reports describing responses in patients 
with central nervous system (CNS) leukemia utilizing 
dasatinib, prompted murine studies comparing imatinib 
and dasatinib. Dasatinib treatment resulted in a notable 
regression of CNS tumor growth and was associated with 
a dose dependent increase in survival when compared with 
untreated controls. Animals treated with imatinib did not 
experience a survival beneﬁ  t and had continued tumor 
growth similar to untreated controls. Although dasatinib 
cerebrospinal ﬂ  uid (CSF) concentrations in these animals 
were 12- to 31-fold lower than simultaneous levels in 
plasma, this concentration was enough to achieve 50% 
inhibition of CML cell lines in vitro. Low CSF concentra-
tions of dasatinib were also observed in 15 patients with 
CML or Ph+ ALL. Only 6 of the 15 patients were found 
to have detectable levels of dasatinib in the CSF when 
measured 3 hours post therapy. Porkka et al. administered 
dasatinib to 14 other patients with imatinib-resistant 
CML in blast crisis or Ph+ ALL with CNS relapse.10 
Eleven of the 14 patients had variable degrees of response Biologics: Targets & Therapy 2009:3 207
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with complete responses in 7 patients. Of note, 5 of the 
14 patients also received concomitant intrathecal che-
motherapy. Three of the 14 patients experienced a CNS 
relapse while on dasatinib therapy and when the CSF of 2 
of these patients was analyzed it was found to contain cells 
with point mutations within the tyrosine kinase known to 
be resistant to dasatinib, suggesting that dasatinib failure 
was due to the selection of a resistant clone.
The reason for clinical efﬁ  cacy despite a modest dasatinib 
concentration in the CSF is unclear at this time but it has 
been theorized that because of dasatinib’s higher potency, 
less drug is required to have an effect. Moreover, it is pos-
sible that the low protein environment of the CSF results in 
a greater unbound fraction of dasatinib. Although the study 
population was small, the ﬁ  ndings are provocative and should 
stimulate future investigations.
Based on its multiple mechanisms of action, a number 
of studies evaluating dasatinib alone or in combination are 
underway in other tumor types, including chronic lympho-
cytic leukemia and lung, colon and prostate cancers.11–16 
Additionally, other studies have utilized dasatinib in patients 
with hyper-eosinophilic syndromes, systemic mastocytosis 
and multiple myeloma.17–19
Dasatinib is primarily metabolized by the CYP3A4 
enzyme pathway and is therefore may be affected by drugs 
that induce or inhibit this pathway. Moreover, dasatinib’s 
solubility is pH dependant and concomitant use of H2 
blockers or proton pump inhibitors is therefore not recom-
mended. Antacids if needed may be used 2 hours before or 
after dasatinib dosing.20
Despite the several theoretical and mechanistic advan-
tages of dasatinib, in vitro studies still indicate that the CML 
pluripotent stem cell continues to be unaffected by tyrosine 
kinase inhibition with dasatinib. Therefore, it is likely that 
discontinuing dasatinib therapy, regardless of the prior 
response achieved, may result in progression of CML.21
Principal non-randomized studies 
utilizing dasatinib
Dasatinib in phase 1 studies
A phase 1 study of dasatinib in 84 imatinib refractory or 
intolerant patients in all phases of disease (chronic phase 
40 patients, accelerated phase 11 patients and blast crisis 
23 patients) as well as Ph+ ALL (10 patients) was completed 
in 2005.1 Patients received dasatinib at doses of 15 to 240 mg 
once daily for 5 days per week. The study allowed for dosage 
escalations, twice-daily dosing and 7-day dosing. The rate 
of major hematologic response was 92% in chronic phase 
CML and 70% in accelerated phase, myeloid blast crisis and 
Ph+ ALL. Cytogenetic responses were also noted with 45% 
of chronic phase patients exhibiting a major cytogenetic 
response (35% complete). In accelerated phase, myeloid 
blast crisis and Ph+ ALL, major cytogenetic responses were 
seen in 27%, 35% and 80% of patients respectively. The 
duration of response was mixed and patients with myeloid 
or lymphoid blast crisis did poorly when compared to those 
in chronic phase and accelerated phase. Only 1 patient in 
lymphoid blast crisis and 3 patients in myeloid blast crisis 
had a durable response and were still in the study at a median 
follow up 4 months. Responses were maintained in 95% 
of patients with chronic phase CML and 82% of patients 
with accelerated phase CML with a median follow-up of 
12 months and 5 months respectively.
Myelosuppression occurred in 45% and 89% of patients 
in chronic phase and advanced phase disease respectively. 
Fifteen patients had pleural effusions related to dasatinib and 
seven patients had transitory liver function abnormalities. 
Importantly, patients who discontinued imatinib due to 
Table 1 Efﬁ  cacy of dasatinib in phase 2 studies among imatinib-resistant patients
N CHR MCyR CCyR Median PFS Median OS Median F/U
Chronic phase24 387 90% 55% 53% NR 75% of pts 
w/o progression 
at 24 months





174 45% 39% 32% NR 66% of pts 
w/o progression 
at 12 months





109 26% Data from 
8 months f/u28
34% 26% 6.7 months 11.8 12 months
Lymphoid blast 
crisis29
48 26% Data from 
8 months f/u28
50% 43% 3.0 months 5.3 12 months
Abbreviations: CHR, complete hematologic response; CCyR, complete cytogenetic response; MCyR, major cytogenetic response rate; PFS, progression-free survival; OS, 
overall survival.Biologics: Targets & Therapy 2009:3 208
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toxicity did not necessarily have recurrence of these toxici-
ties with dasatinib. Dasatinib therapy produced hematologic 
and cytogenetic responses in all of the patients with BCR-
ABL mutations associated with imatinib resistance with the 
exception of the T315I mutation.1
Based on these ﬁ  ndings and dasatinib’s relatively short 
half-life (3–5 hours),22 three phase 2 studies were initiated 
evaluating dasatinib in chronic, accelerated and blast phases 
using doses of 70 mg twice a day.
Dasatinib in chronic phase
The results of a phase 2 open label international study of 
387 patients with chronic phase CML who were resistant 
or intolerant of imatinib was published in early 2008.23 At 
a median follow-up of 15.2 months, complete hematologic 
responses (CHR) were achieved in 90% of imatinib-resistant 
patients with 52% achieving a major cytogenetic response 
rate (MCyR). The time to CHR was rapid with the majority 
of patients achieving CHR within 15 days. The most com-
mon reason for discontinuation of dasatinib was toxicity 
(13%) followed by disease progression (7%).2 In the most 
recent update with a minimum follow-up of 24 months, 
the MCyR was 55% with 88% of patients who achieved a 
MCyR maintaining this level of response for at least 2 years. 
Progression-free survival at 24 months for imatinib-resistant 
patients was 75%.24
Thus, approximately half of patients with chronic phase 
CML with imatinib resistance or intolerance have signiﬁ  cant 
and durable cytogenetic responses with dasatinib therapy. 
Further therapeutic considerations for nonresponders include 
alternative tyrosine kinase inhibitors and allogeneic trans-
plantation if feasible. The optimal management of those 
achieving complete cytogenetic response (CCyR) is less 
clear. Given the relatively short follow-up, there is no guar-
antee that these patients will not eventually progress, and 
consequently the role of transplantation for these responding 
patients continues to be debated. Certainly these patients 
should be monitored closely by quantitative PCR assays 
for signs of relapse to avoid delays in beginning alternative 
measures.25 For those who are not transplant candidates, 
however, these results are particularly encouraging and 
suggestive of the possibility that therapy with dasatinib may 
result in long-term disease control.
Dasatinib in accelerated phase
Patients with CML in accelerated phase were evaluated 
in another phase II open label multinational trial which 
included patients with imatinib resistance or intolerance. 
Dasatinib was given at a dose of 70 mg twice daily until 
evidence of disease progression. A preliminary assessment 
of efﬁ  cacy and safety performed on the ﬁ  rst 107 patients 
with at least 8 months of follow-up was published in 2007.26 
The majority of patients (68%) had been treated for at least 
3 years with imatinib and 59% had been treated with greater 
than 600 mg per day of imatinib.
In the most recent update of efﬁ  cacy and safety in 
174 patients with a median follow up of 14.1 months, 
45% of patients achieved a CHR. Additionally, 39% of 
patients with imatinib resistance had a MCyR with 32% 
of patients achieving a CCyR. Twelve-month progres-
sion-free survival and overall survival were 66% and 
82%, respectively.27 Despite these encouraging results, it 
must be noted that the follow-up period is relatively short 
and that the majority of patients (61%) did not achieve 
a major cytogenetic response, an important predictor of 
long term response for de novo CML patients treated with 
imatinib. In addition, 19% of patients did not respond to 
therapy and there is no indication that the progression-
free survival curves have begun to plateau suggesting 
that responses may be short lived.26 For these reasons, 
allogeneic transplant should be considered for patients in 
accelerated phase. The search for compatible donors may 
be time consuming and therefore our institution begins 
this process when second generation TKIs are started in 
patients in accelerated phase.
Dasatinib in myeloid or lymphoid 
blast crisis
A third open label phase 2 trial evaluated patients in myeloid 
blast crisis (MBC) or lymphoid blast crisis (LBC) after ima-
tinib failure or intolerance. The initial analysis with 8 months 
of follow up for the 74 patients in MBC and the 42 patients 
with LBC noted that only 43% and 12% of patients respec-
tively, remained on study.28 The median duration of therapy 
was 3.4 months for all patients and the most recent update 
with 109 and 48 patients in MBC and LBC respectively 
showed that major hematologic responses (MaHRs) were 
induced in 34% of patients with MB-CML and in 35% of 
LB-CML patients. MCyR were attained in 33% of patients 
with MB-CML and 52% of LB-CML patients, while CCyR 
were achieved in 26% (imatinib-resistant 26%, intolerant 
20%) and 46% of patients (imatinib-resistant 43%, intolerant 
67%), respectively. Median progression-free survival was 
6.7 months (MB-CML) and 3.0 months (LB-CML) while 
median overall survival was 11.8 months and 5.3 months, 
respectively.29Biologics: Targets & Therapy 2009:3 209
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It is evident that despite advanced stages of disease, a pro-
portion of patients do respond to dasatinib therapy. However, 
most of these responses are short lived and the majority of 
patients fail to respond. There appears to be a constant decline 
in the progression-free survival curves indicating that most 
of these patients will rapidly require additional therapies. As 
a consequence, patients in blast crisis should be evaluated 
for consideration of stem cell transplantation when therapy 
with dasatinib is initiated.
Dasatinib in Ph+ ALL
Murine models have suggested that tyrosine kinase activity 
is an important driver of leukomogenicity in Ph+ ALL.30 
A phase 2 study evaluating single agent dasatinib in 34 
Ph+ ALL patients with imatinib resistance, resulted in 58% of 
patients achieving a CCyR with a minimum of 8 months of 
follow-up. The median progression-free survival was rela-
tively short at 3.3 months, however. These ﬁ  ndings clearly 
showed the activity of dasatinib in this population and stud-
ies utilizing dasatinib in the front-line setting as well as in 
combination with chemotherapy were initiated.31,32 In par-
ticular, the combination of Hyper-CVAD and dasatinib was 
evaluated in a phase 2 study of newly diagnosed or relapsed 
Ph+ ALL. Data from the American Society of Hematology 
meeting in 2007 was presented for 15 newly diagnosed and 
4 relapsed Ph+ ALL patients. Dasatinib was given at a dose 
of 50 mg twice daily with maintenance dasatinib, vincristine 
and prednisone for those in complete remission. All patients 
with relapsed disease achieved a complete response after the 
ﬁ  rst cycle with 3 of the patients achieving a CCyR. Addition-
ally, 13 of the 14 evaluable patients with newly diagnosed 
ALL achieved a complete response with 1 cycle of therapy. 
Moreover, 10 of 11 evaluable patients achieved a CCyR.32 
These results are clearly very early and may be affected by 
the small sample size but do indicate that dasatinib can be 
given in combination with chemotherapy in newly diag-
nosed Ph+ ALL. Further information about the duration 
of responses is needed and at this time most clinicians rec-
ommend allogeneic transplantation if possible when these 
patients achieve remission.
Toxicity and side effects 
of dasatinib therapy
The most common side effects of dasatinib therapy in the 
phase II studies were hematologic and included grade 3–4 
neutropenia in 50% of chronic phase patients and 76% of accel-
erated phase patients. Thrombocytopenia was also common 
with 49% of patients in chronic phase and 82% of accelerated 
phase patients having grade 3–4 thrombocytopenia.23,24,26,27,33 
The majority of blast crisis patients developed cytopenias with 
8% of patients having an episode of febrile neutropenia.28,29 
Non hematologic toxicities included pleural effusions in 
27% of patients with chronic and accelerated phase.23,24,26,27,33 
Grade 3–4 non-malignant pleural effusions occurred in 9%, 
5%, and 21% of patients in chronic phase, accelerated phase 
and blast crisis respectively.23,24,26–29,33 Pleural effusions were 
observed more frequently in the MB-CML cohort, with all 
grade pleural effusion occurring in 36% and 13% of MB and 
LB patients, respectively.28,29
Pleural effusions appear to be a unique side effect of 
dasatinib and occur only rarely with imatinib or other tyrosine 
kinase inhibitors. The mechanism is postulated to be related 
to “off target” kinase inhibition. For example, CDP860, 
a compound engineered to block the activity of the beta- 
subunit of the platelet derived growth factor receptor has 
been shown to result in effusions when treating other tumor 
types34 Other possibilities include interruption of vascular 
permeability and autoimmune mechanisms.35,34 Additionally, 
some patients developed pericardial effusions and pulmonary 
inﬁ  ltrates. The management of pleural effusions includes 
close monitoring and diuresis for grade 1 (asymptomatic) 
effusions whereas grade 2 and 3 effusions often require 
thoracentesis as well as dose interruption, loop diuretics and 
steroids. For those with recurrent effusions, repeat drainage, 
shunt placement and chemical pleurodesis may be necessary 
if it is felt that the beneﬁ  ts of continued therapy outweigh 
the risks involved. Patients with a prior cardiac history, 
hypertension and those receiving twice daily therapy have 
an increased risk of developing this toxicity.34 Patients with a 
history of autoimmune disease may also be at higher risk for 
development of effusions.35 Other notable treatment-related 
side effects included nausea, rash, gastrointestinal bleeding, 
diarrhea, fatigue, headache, superﬁ  cial edema and elevations 
of liver enzymes. The majority of these were low grade.
A less common and as yet poorly characterized phenom-
enon is the sudden development of lymphocytosis in patients 
taking dasatinib.36 In vitro data have suggested that dasatinib 
has immunomodulatory effects on T cells and it has been 
suggested that this may be a result of “off target” tyrosine 
kinase inhibition. This phenomenon is particularly intrigu-
ing because Src kinase inhibition was theorized to induce 
lymphopenia and decrease thymocyte differentiation.37 After 
a median of 3 months from the start of dasatinib therapy an 
abrupt lymphocytosis (peak 4–20 × 109/L) was observed in 
18 patients, none of whom had developed lymphocytosis 
while taking imatinib. These lymphocytes had morphologic Biologics: Targets & Therapy 2009:3 210
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characteristics of large granular lymphocytes (LGL) and in 
13 of 18 patients a proliferation of clonal cytotoxic T cells 
was demonstrated by immunophenotyping. The remainder 
of patients displayed a clonal natural killer cell phenotype. 
It was noted that the rate of adverse events such as pleuri-
tis and colitis among these patients was rather high (16 of 
18 patients) and clonal cytotoxic T cells were noted on biopsy 
specimens of some patients who developed colitis as well 
as in pleural effusion samples.37 It was also observed that 
patients developing a clonal lymphocyte expansion seemed to 
have relatively favorable responses which included complete, 
long-lasting molecular responses in patients with advanced 
leukemia.36 Indeed, we have observed this as well in one of 
our own patients with myeloid blast crisis who has remained 
in CyCR for 3 years with a T/NK lymphocytosis. The inci-
dence of lymphocytosis and whether it is indeed associated 
with “inﬂ  ammatory” type toxicities and improved response 
in patients, presumably by immune mediated mechanisms, 
needs to be evaluated in larger groups of patients and hope-
fully such analyses of the large number of patients on the 
dasatinib trials will be forthcoming shortly.
Dose optimization with dasatinib
The three phase 3 studies evaluating dasatinib utilized a 
dose of 70 mg bid based on its relatively short half-life 
(3–5 hours) and earlier pharmacokinetic and pharmacody-
namic studies. However, in the phase 1 study, hematologic 
and cytogenetic responses were also noted with once-a-day 
dosing. Moreover, as a result of dose reductions, the median 
daily dose of dasatinib in the phase I study was 101 mg.1,38 
Longer-term follow-up also suggested that pleural effusions 
were less common with once-daily dosing.38 Consequently, 
a phase III randomized trial evaluating different doses and 
schedules of dasatinib in patients with imatinib-intolerant 
or -resistant chronic phase CML was conducted.38 Seven 
hundred and twenty-four patients were randomized to receive 
100 mg daily, 140 mg daily, 50 mg twice daily or 70 mg 
twice daily. Dose escalations and reductions were allowed 
for inadequate response and toxicity. With a minimum 
follow-up of 6 months and a median duration of therapy 
of 8 months, there was no difference in the rates of CHR, 
MCyR, progression-free survival, overall survival or disease 
progression among the four arms.
The rates of key treatment-related adverse events 
(ie, cytopenias and pleural effusions) were consistently 
lower in patients receiving dasatinib 100 mg once daily than 
for the other treatment groups. Overall, signiﬁ  cantly fewer 
patients treated with the 100 mg once daily dose experienced 
grade 3–4 adverse events when compared to patients 
receiving the currently approved 70-mg twice-daily dose 
(30% vs 48%; p  0.001). In particular, grade 3/4 throm-
bocytopenia was decreased (22% vs 37%; p  0.004). The 
currently approved dosing schedule of 70 mg twice daily 
had signiﬁ  cantly higher rates of pleural effusion (any grade) 
compared with the 100 mg once-daily arm (16% vs 7% 
p = 0.024) as well as higher incidences of nausea (25% vs 
15%) and vomiting(10% vs 5%). As a result, fewer patients 
in the 100 mg daily-dose arm had dosage reductions (22% vs 
32%) or interruptions (27% vs 35%) compared with the 
70 mg twice-daily arm. Additionally, discontinuation owing 
to toxicity occurred in only 4% of patients treated with 
100 mg once daily as compared with 11% of patients treated 
with 70 mg twice daily.
These results indicated that the 100 mg daily dosing regi-
men offered the best risk/beneﬁ  t ratio of the doses compared. 
Although the follow-up is relatively short, these ﬁ  ndings 
are consistent with the early results of the phase 2 studies 
investigating dasatinib. It should be noted that these results 
are for patients in chronic phase and that higher doses may 
be necessary to achieve adequate responses in more advanced 
disease. The current recommended starting dose continues to 
be 70 mg twice a day in patients with accelerated and blast 
crisis CML. A similarly designed dose optimization study 
in accelerated and blast phase CML is underway and has 
completed accrual.39
Principal clinical studies comparing 
dasatinib with other therapies
Dasatinib versus other TKIs
Prior to the availability of second-generation TKIs, the 
most commonly utilized therapy for imatinib-resistant CML 
patients was dose escalation. A phase 2 study evaluated the 
relative beneﬁ  t of 70 mg of dasatinib twice daily versus a 
dose escalation to 800 mg of imatinib.40 One hundred and 
ﬁ  fty patients with chronic phase CML whose disease had 
progressed on 400 to 600 mg/day of imatinib were random-
ized in a 2:1 ratio to dasatinib or dose-escalated imatinib. 
Patients with mutations known to have a high resistance to 
imatinib were excluded and crossover was allowed if there 
was conﬁ  rmed progression, lack of MCyR at 12 weeks, or 
intolerance despite dose reduction. More than two-thirds of 
patients had received treatment with 600 mg of imatinib. 
With a median follow-up of 15 months, CHR and CCyR 
were found to be signiﬁ  cantly more common in the dasatinib 
arm (Table 2). Major molecular responses were also more 
frequent with dasatinib (16% vs 4%, p = 0.038).Biologics: Targets & Therapy 2009:3 211
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Patients with the highest pre-study likelihood of imatinib 
resistance, namely those unable to achieve a MCyR on 
imatinib and those progressing on 600 mg of imatinib daily, 
had signiﬁ  cantly higher rates of MCyR with dasatinib use. 
However, the rates of MCyR in those who receiving 400 
mg of imatinib daily prior to enrollment were similar for 
the dose escalation or dasatinib population (53% vs 58%) 
(Table 3). The median time to treatment failure and response 
after crossover favored the dasatinib arm. The most common 
reason for imatinib discontinuation was disease progression 
(61%) whereas discontinuation of dasatinib was most often 
due to intolerance (16%). Progression-free survival showed 
an 86% relative risk reduction in favor of dasatinib.
Grade 3–4 non-hematologic toxicity was minimal for both 
treatment groups. All-grade superﬁ  cial edema (15% vs 43%) 
and ﬂ  uid retention (30% vs 45%) were less common with 
dasatinib than imatinib, whereas pleural effusion (17% vs 
0%; grade 3–4, 4% vs 0%) was more common. Cytopenias, 
particularly thrombocytopenia, was more profound in the 
dasatinib group. These data suggest that in those patients 
who are unable to achieve MCyR with imatinib or in those 
patients failing to respond to 600 mg of imatinib daily, the 
preferred second-line therapy is a second-generation TKI. 
In patients who do not respond to 400 mg of imatinib daily 
or in those who progress at this dose, both dose escalation 
or switching to a second-generation TKI remain reasonable 
alternatives.
Dasatinib versus hematopoietic 
stem cell transplantation
A retrospective analysis of 420 patients who failed imatinib 
therapy was performed with the goal of evaluating the most 
promising second-line therapy.41 Outcomes were grouped 
by the patient’s phase of disease at the time of relapse. 
Eighty-eight patients had progressed on imatinib but 
remained in chronic phase. The outcomes of these patients 
were the most encouraging, with 3-year survival rates of 
72% regardless of the type of second-line therapy chosen. 
Patients who were in accelerated phase at the time of progres-
sion or progressed to accelerated phase from chronic phase 
while on imatinib therapy, had a 3-year survival of only 30%, 
whereas patients progressing to blast crisis or remaining in 
blast crisis with imatinib resistance performed poorly with 
3-year survival rates of only 7%.
Patients who remained in chronic phase at the time of 
progression appeared to do better with second generation 
TKIs rather than allogeneic stem cell transplant. In a mul-
tivariable analysis however, second-line therapy was not 
identiﬁ  ed as an independent prognostic factor for survival 
possibly due to the limited follow-up and the multiple, poorly 
characterized reasons why some patients were referred for 
transplantation and others not. This retrospective analysis in 
combination with the results of the dasatinib study in chronic 
phase mentioned earlier lends support to the notion that some 
patients in chronic phase may do well with dasatinib therapy 
alone. Additionally, this study supports the inferences from 
the phase 2 studies that patients with more advanced disease 
have relatively poor outcomes with dasatinib alone and that 
stem cell transplantation should be considered. However, 
this study does not provide insight into whether patients who 
respond to dasatinib beneﬁ  t from transplantation as compared 
to continued treatment with dasatinib.
Other alternatives to dasatinib
Nilotinib
Nilotinib (formerly AMN107) is an orally active amino-
pyrimidine- derivative tyrosine kinase inhibitor with 20 to 
50 times the inhibitory activity of imatinib in imatinib sensi-
tive cell lines. Like imatinib, nilotinib binds only the active 
conformation of the kinase molecule and functions through 
competitive inhibition at the ATP binding site. Nilotinib 
has been shown to be active against 32 of 33 mutations 
found in the BCR-ABL kinase domain.42 The only mutation 
found to be unaffected by nilotinib usage is, as in the case 
Table 2 Dasatinib versus 800 mg imatinib: all patients40








Dasatinib 100 93 52% 40% 45% NR 15 months
Imatinib 800 mg 50 82 33% 16% 15% 3.5 months 
(CI, 3.3–3.8 months)
15 months
p value 0.034 0.023 0.004 0.063
Abbreviations: CHR, complete hematologic response; CCyR, complete cytogenetic response; MCyR, major cytogenetic response rate.Biologics: Targets & Therapy 2009:3 212
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of dasatinib, the T315I mutation. Based on phase 1 studies, 
a dose of 400 mg twice daily was thought to be optimal for 
phase 2 evaluation.
In the most recent update of a phase 2 trial of nilotinib 
in 320 patients with imatinib failure in chronic phase who 
had received nilotinib for at least 6 months, the CHR 
rate, MCyR rate and CCyR rate were 76%, 56% and 40% 
respectively.43 Nilotinib was also evaluated in 119 patients 
in accelerated phase CML. With all patients receiving at 
least 6 months of therapy, only 26% of patients achieved a 
CHR. MCyR and CCyR were noted in 29.4% and 16% of 
patients respectively.44 One hundred thirty-ﬁ  ve imatinib-
resistant patients with blast crisis were also evaluated in a 
phase II study and found to have a CHR in 24% of patients 
with MBC and 28% of patients with LBC. However, it was 
noted that 88% of patients discontinued therapy at a median 
of 84 days largely due to disease progression.45 Cytopenias 
were the most common toxicity43–45 and non-hematologic side 
effects included liver function abnormalities (predominantly 
asymptomatic unconjugated hyperbilirubinemia), rash as 
well as asymptomatic lipase elevations in ∼15% patients.42–45 
QT prolongation noted in the phase 1 study was not an issue 
in the follow up phase 2 populations.7
None of these studies utilized an additional control or 
experimental arm and inferences about the efﬁ  cacy of nilotinib 
comparison with dasatinib are speculative, although the 
response rates seem to be in the same range. Therefore, unless 
a randomized study is performed (an unlikely prospect), no 
data support the preferential use of either TKI for patients 
with imatinib-resistant CML. An exception may be for certain 
mutations which have better in vitro sensitivity to one agent 
or another such as P-loop and F359I/V mutations, which are 
more sensitive to dasatinib, and F317L mutations which are 
more sensitive to nilotinib.46 Additionally, drug selection should 
also be based on side-effect proﬁ  le. For example, for patients in 
whom there might be increased concern about ﬂ  uid retention, 
nilotinib may be the more suitable choice, whereas for patients 
with a history of pancreatitis, dasatinib might be preferred.
Emerging therapies
There are a number of emerging therapies which may improve 
on the current treatments for CML. They can be organized 
into 3 broad categories. The ﬁ  rst is the use of tyrosine kinase 
inhibitors in combination with other therapies to improve 
remission rates and discourage the development of resistance. 
Combination therapy may result in inhibition of critical down-
stream events responsible for imatinib resistance. For instance, 
it has been shown that the PI3K/Akt pathway is important in 
this process and the serine/threonine protein kinase mTOR 
is a downstream component of this pathway. In BCR-ABL 
positive cells the mTOR pathway is constitutively active, 
resulting in phosphorylation of its substrates. Inhibition of this 
mechanism with rapamycin, an mTOR inhibitor has shown 
activity against imatinib-resistant cell lines.47 Combination 
therapy with mTOR inhibitors and imatinib may result in 
fewer frontline failures and therapy may be well tolerated.
A second possibility is the development of additional 
BCR-ABL inhibitory TKIs with different kinase inhibition 
proﬁ  les compared to imatinib and second generation TKIs. 
Examples include bosutinib, which inhibits Src family kinases 
but not KIT or PDGFR, and INNO-406 which inhibits ARG 
and FYN kinases.7 As newer drugs are identiﬁ  ed for refrac-
tory disease, they are also being tested in previously untreated 
patients as well. Studies comparing dasatinib, nilotinib and 
bosutinib to imatinib in newly diagnosed chronic phase CML 
are underway.48–50,54 If durable cytogenetic response rates are 
signiﬁ  cantly improved with the use of these medications in 
the front line setting, it is possible that a smaller percentage 
of patients will ultimately develop treatment resistance.
Lastly, new small molecule non-ATP-competitive 
inhibitors designed to address the T315I mutation are under 
development.6 In vitro results are intriguing and phase 1 trials 
are being initiated.
Conclusions
Therapy with imatinib has revolutionized the treatment of 
CML although “only” ∼65% of chronic phase patients remain 
Table 3 Response to dasatinib stratiﬁ  ed by prior therapy and response40
All patients Failed to achieve MCyR to imatinib Prior imatinib dose  600 mg Prior imatinib dose = 400 mg
Dasatinib N = 101 N = 39 N = 63 N = 38
MCyR 52% 49% 49% 58%
Imatinib N = 49 N = 15 N = 34 N = 14
MCyR 33% 7% 24% 53%
p value 0.023 0.006 0.015 NS
Abbreviation: MCyR, major cytogenetic response rate.Biologics: Targets & Therapy 2009:3 213
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
in CCyR on imatinib after 5 years of treatment, leaving 
some room for improvement.4 Dasatinib has emerged as an 
effective second-line therapy for many of these imatinib-
resistant patients. However, ∼50% of imatinib-resistant 
chronic phase patients do not have cytogenetic responses 
with dasatinib treatment and the responses in more advanced 
stages are generally not durable. Thus, hematopoietic stem 
cell transplantation must be considered in non-responders to 
dasatinib and in those in more advanced stages. Additionally, 
despite the several theoretical and mechanistic advantages of 
dasatinib, in vitro studies still indicate that the CML stem cell 
continues to be unaffected by tyrosine kinase inhibition with 
dasatinib. Therefore, it can be theorized that discontinuing 
therapy, regardless of the response achieved, may result in 
progression of CML.21
The role of second-generation TKIs in newly diagnosed 
patients is currently being evaluated. Preliminary results 
are promising for both drugs. Nilotinib and dasatinib were 
evaluated in patients with untreated chronic phase CML and 
produced favorable early results compared with historical 
data with imatinib. Ninety-five percent of 32 patients 
achieved CCyR after 3 months of therapy with nilotinib.51 
Dasatinib was evaluated in 37 patients and at 3 months, 79% 
of patients have achieved a CCyR.52 These results along with 
the efﬁ  cacy of these agents in the second-line setting have 
provided the impetus for the randomized phase 3 studies 
mentioned above.53,55
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